Vir/GSK Move Lead Coronavirus Antibody Into Phase III

Safety In 20 Phase II Patients Enabled Testing In 1,300 People

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.

Immunological system, antibodies attacking the virus covid-19. 3D illustration, concept of the body's defense system. Y-shaped antibody attacking the coronavirus.
VIR-7831 is engineered to neutralize SARS-CoV-2, with limited treatment resistance, enhanced lung bioavailability and an extended half-life • Source: Shutterstock

Vir Biotechnology, Inc. and GlaxoSmithKline plc are taking VIR-7831 (GSK4182136) – an antibody therapy against SARS-CoV-2 – into Phase III testing based on safety results from the Phase II lead-in to the Phase II/III COMET-ICE clinical trial. Initial data from the registrational Phase III portion of the trial seeking to prevent hospitalization of COVID-19 patients may be available before the end of 2020 with complete results expected in January 2021, the companies said on 6 October.

Vir chief medical officer Phil Pang told Scrip that the COMET-ICE independent data monitoring committee reviewed safety data from 20...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains